Edition:
India

Bio Path Holdings Inc (BPTH.OQ)

BPTH.OQ on NASDAQ Stock Exchange Capital Market

11.69USD
20 Sep 2019
Change (% chg)

$-0.03 (-0.26%)
Prev Close
$11.72
Open
$11.72
Day's High
$12.10
Day's Low
$11.54
Volume
24,096
Avg. Vol
34,890
52-wk High
$73.52
52-wk Low
$1.63

Latest Key Developments (Source: Significant Developments)

Bio-Path Holdings Reports Second Quarter 2019 Financial Results
Thursday, 15 Aug 2019 

Aug 15 (Reuters) - Bio Path Holdings Inc ::BIO-PATH HOLDINGS REPORTS SECOND QUARTER 2019 FINANCIAL RESULTS.Q2 LOSS PER SHARE $0.87.AS OF JUNE 30, 2019, COMPANY HAD CASH OF $17.1 MILLION.  Full Article

Bio Path Holdings Files For Stock Shelf Of Up To $125 Mln
Friday, 17 May 2019 

May 16 (Reuters) - Bio Path Holdings Inc ::BIO PATH HOLDINGS FILES FOR STOCK SHELF OF UP TO $125 MILLION - SEC FILING.  Full Article

Bio-Path Holdings Q1 Loss Per Share $0.89
Thursday, 16 May 2019 

May 16 (Reuters) - Bio Path Holdings Inc ::BIO-PATH HOLDINGS REPORTS FIRST QUARTER 2019 FINANCIAL RESULTS.Q1 LOSS PER SHARE $0.89.AS OF MARCH 31, 2019, COMPANY HAD CASH OF $19.3 MILLION, COMPARED TO $1.0 MILLION AT DECEMBER 31, 2018.  Full Article

Bio-Path Holdings, Inc. Announces $1.7 Million Registered Direct Offering
Friday, 18 Jan 2019 

Jan 18 (Reuters) - Bio Path Holdings Inc ::BIO-PATH HOLDINGS, INC. ANNOUNCES $1.7 MILLION REGISTERED DIRECT OFFERING PRICED AT-THE-MARKET.ENTERED AGREEMENTS WITH INSTITUTIONAL INVESTORS FOR ISSUANCE AND SALE OF 648,302 SHARES OF COMMON STOCK AT $2.65/SHARE.  Full Article

Bio-Path Holdings Provides Clinical Update And 2019 Business Outlook
Thursday, 27 Dec 2018 

Dec 27 (Reuters) - Bio Path Holdings Inc ::BIO-PATH HOLDINGS PROVIDES CLINICAL UPDATE AND 2019 BUSINESS OUTLOOK.BIO PATH HOLDINGS - EXPECTS TO INITIATE PHASE 1 CLINICAL TRIAL OF BP1002 IN REFRACTORY OR RELAPSED LYMPHOMA AND CLL PATIENTS IN 2019.BIO PATH HOLDINGS INC - IN 2019, BIO-PATH INTENDS TO INITIATE A PHASE 1 CLINICAL TRIAL OF PREXIGEBERSEN IN PATIENTS WITH ADVANCED SOLID TUMORS.  Full Article

Bio-Path Holdings reports third quarter results
Thursday, 15 Nov 2018 

Nov 15 (Reuters) - Bio Path Holdings Inc ::BIO-PATH HOLDINGS REPORTS THIRD QUARTER 2018 FINANCIAL RESULTS.Q3 LOSS PER SHARE $0.27.AS OF SEPTEMBER 30, 2018, COMPANY HAD CASH OF $2.3 MILLION, COMPARED TO $6.0 MILLION AT DECEMBER 31, 2017.  Full Article

Bio-Path Holdings Announces $1.5 Mln Registered Direct Offering
Friday, 21 Sep 2018 

Sept 21 (Reuters) - Bio Path Holdings Inc ::BIO-PATH HOLDINGS, INC. ANNOUNCES $1.5 MILLION REGISTERED DIRECT OFFERING.BIO PATH HOLDINGS - ENTERED INTO DEFINITIVE AGREEMENTS WITH SEVERAL HEALTHCARE FOCUSED INVESTORS FOR SALE OF 2.3 MILLION SHARES FOR $0.65 PER SHARE.  Full Article

Bio-Path Holdings Reports Full Year 2017 Financial Results
Tuesday, 3 Apr 2018 

April 3 (Reuters) - Bio Path Holdings Inc ::PATH HOLDINGS REPORTS FULL YEAR 2017 FINANCIAL RESULTS.  Full Article

Bio-Path Holdings Announces Interim Data From Phase 2 Clinical Trial Of Prexigebersen
Tuesday, 3 Apr 2018 

April 3 (Reuters) - Bio Path Holdings Inc ::PATH HOLDINGS ANNOUNCES INTERIM DATA FROM PHASE 2 CLINICAL TRIAL OF PREXIGEBERSEN IN COMBINATION WITH LOW DOSE CYTARABINE (LDAC) FOR THE TREATMENT OF ACUTE MYELOID LEUKEMIA (AML).BIO PATH HOLDINGS INC - PREXIGEBERSEN PLUS LDAC WAS WELL-TOLERATED.LEUKEMIC ACTIVITY IN NEARLY 50% OF EVALUABLE AML PATIENTS TREATED TO DATE​.‍ AMENDING PROTOCOL TO CHANGE DOSING SCHEDULE TO THAT USED IN PHASE 1B STUDY IN RELAPSED AND REFRACTORY AML PATIENTS​.  Full Article

Bio-Path Holdings Announces 1-For-10 Reverse Stock Split
Friday, 9 Feb 2018 

Feb 9 (Reuters) - Bio Path Holdings Inc ::BIO-PATH HOLDINGS ANNOUNCES 1-FOR-10 REVERSE STOCK SPLIT.BIO PATH HOLDINGS - REVERSE STOCK SPLIT BECAME EFFECTIVE AT 5:00 PM EASTERN TIME ON FEBRUARY 8, 2018.  Full Article